Lisa D. Johnson

1.9k total citations
31 papers, 771 citations indexed

About

Lisa D. Johnson is a scholar working on Immunology, Oncology and Physiology. According to data from OpenAlex, Lisa D. Johnson has authored 31 papers receiving a total of 771 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Immunology, 7 papers in Oncology and 5 papers in Physiology. Recurrent topics in Lisa D. Johnson's work include Phagocytosis and Immune Regulation (13 papers), Immune Cell Function and Interaction (9 papers) and Immunotherapy and Immune Responses (9 papers). Lisa D. Johnson is often cited by papers focused on Phagocytosis and Immune Regulation (13 papers), Immune Cell Function and Interaction (9 papers) and Immunotherapy and Immune Responses (9 papers). Lisa D. Johnson collaborates with scholars based in United States, Canada and United Kingdom. Lisa D. Johnson's co-authors include Stephen C. Jameson, Adovi Akue, Lindsey M. Pujanauski, Ross M. Kedl, Catherine Haluszczak, Sara E. Hamilton, Robert A. Uger, Shuquan Chen, Jeanne Mendell and Penka S. Petrova and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Lisa D. Johnson

30 papers receiving 759 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lisa D. Johnson United States	15	557	206	111	62	52	31	771
Magda Lourda Sweden	12	280 0.5×	269 1.3×	239 2.2×	70 1.1×	11 0.2×	23	644
Pernilla Jirholt Sweden	16	282 0.5×	74 0.4×	448 4.0×	38 0.6×	18 0.3×	27	847
Elisabeth Ludwig Germany	10	281 0.5×	156 0.8×	113 1.0×	40 0.6×	119 2.3×	13	573
Georgia Fousteri Italy	18	562 1.0×	159 0.8×	227 2.0×	27 0.4×	11 0.2×	50	978
Søren Ulrik Sønder United States	11	268 0.5×	77 0.4×	100 0.9×	74 1.2×	43 0.8×	15	484
Lindsay Fowles Australia	11	175 0.3×	89 0.4×	318 2.9×	17 0.3×	20 0.4×	20	538
Erin Stevens United States	6	285 0.5×	32 0.2×	95 0.9×	30 0.5×	54 1.0×	7	475
Etienne Foucher France	10	364 0.7×	227 1.1×	82 0.7×	17 0.3×	26 0.5×	18	591
Todd Douglas Canada	11	333 0.6×	123 0.6×	455 4.1×	32 0.5×	17 0.3×	12	652
A. Christopher Stevens United States	11	304 0.5×	133 0.6×	111 1.0×	45 0.7×	24 0.5×	13	789

Countries citing papers authored by Lisa D. Johnson

Since Specialization

Citations

This map shows the geographic impact of Lisa D. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa D. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa D. Johnson more than expected).

Fields of papers citing papers by Lisa D. Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa D. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa D. Johnson. The network helps show where Lisa D. Johnson may publish in the future.

Co-authorship network of co-authors of Lisa D. Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa D. Johnson. A scholar is included among the top collaborators of Lisa D. Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa D. Johnson. Lisa D. Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Krishnamoorthy, Mithunah, Ruth Seelige, Christopher R. Brown, et al.. (2025). Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy. Frontiers in Immunology. 16. 1518787–1518787.

Johnson, Lisa D., Marlen Metzner, François G. Kavelaars, et al.. (2024). Mutational Landscape and Depth of Response in Patients with Acute Myeloid Leukemia (AML) Treated with Magrolimab in Combination with Venetoclax and Azacitidine Compared to Placebo. Blood. 144(Supplement 1). 2914–2914. 1 indexed citations

Ni, Ying, Lisa D. Johnson, Peter G. Rose, et al.. (2023). Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition. npj Precision Oncology. 7(1). 69–69. 14 indexed citations

Kruglov, Oleg, Lisa D. Johnson, Kimberly R. Jordan, et al.. (2021). The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides. Cancer Immunology Immunotherapy. 71(4). 919–932. 8 indexed citations

Johnson, Lisa D., et al.. (2020). Goat γδ T cell subpopulations defined by WC1 expression, responses to pathogens and cytokine production. Developmental & Comparative Immunology. 118. 103984–103984. 12 indexed citations

Kruglov, Oleg, Lisa D. Johnson, Robert A. Uger, et al.. (2019). Anti-CD7 immunotherapy is mediated by cytotoxic CD107a+IFN-γ– NK cells and can be potentiated by interferon-α in cutaneous lymphoma. European Journal of Cancer. 119. S33–S33. 1 indexed citations

Jansen, Mendel, Steve Warrington, Victor Dishy, et al.. (2018). A Randomized, Placebo‐Controlled, Double‐Blind Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeated Doses of Mirogabalin in Healthy Asian Volunteers. Clinical Pharmacology in Drug Development. 7(6). 661–669. 20 indexed citations

Querfeld, Christiane, John A. Thompson, Matthew H. Taylor, et al.. (2017). A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 Do Not Eat Signal. Blood. 130. 4076–4076. 15 indexed citations

Ray, Roberta M., et al.. (2017). ASSOCIATIONS BETWEEN EXERCISE PRIOR TO AND AROUND THE TIME OF CANCER DIAGNOSIS AND SUBSEQUENT CARDIOVASCULAR EVENTS IN WOMEN WITH BREAST CANCER: A WOMEN'S HEALTH INITIATIVE (WHI) ANALYSIS. Journal of the American College of Cardiology. 69(11). 1774–1774. 14 indexed citations

10.

Lin, Gloria H. Y., Vivian Lee, Karen Dodge, et al.. (2017). TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets. PLoS ONE. 12(10). e0187262–e0187262. 51 indexed citations

11.

Lin, Gloria H. Y., Hui Chen, Mark Wong, et al.. (2017). Abstract 2646: Intratumoral delivery of TTI-621 (SIRPαFc), a CD47-blocking immunotherapeutic, inhibits tumor growth and prolongs animal survival in a subcutaneous B cell lymphoma model. Cancer Research. 77(13_Supplement). 2646–2646. 1 indexed citations

12.

Thompson, John A., Oleg E. Akilov, Christiane Querfeld, et al.. (2017). A phase 1 dose-escalation trial of intratumoral TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides.. Journal of Clinical Oncology. 35(15_suppl). TPS3101–TPS3101. 4 indexed citations

13.

Lin, Gloria H. Y., Vivian Lee, Karen Dodge, et al.. (2016). Abstract 2345: SIRPαFc, a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by both classically (M1) and alternatively (M2) activated macrophages. Cancer Research. 76(14_Supplement). 2345–2345. 1 indexed citations

14.

Mendell, Jeanne, Lisa D. Johnson, & Shuquan Chen. (2015). An open‐label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. The Journal of Clinical Pharmacology. 55(12). 1395–1405. 48 indexed citations

15.

Johnson, Lisa D., Nancy J. Nesslinger, Paul Blood, et al.. (2014). Tumor-associated autoantibodies correlate with poor outcome in prostate cancer patients treated with androgen deprivation and external beam radiation therapy. OncoImmunology. 3(6). e29243–e29243. 4 indexed citations

16.

Johnson, Lisa D. & Stephen C. Jameson. (2012). TGF-β Sensitivity Restrains CD8+ T Cell Homeostatic Proliferation by Enforcing Sensitivity to IL-7 and IL-15. PLoS ONE. 7(8). e42268–e42268. 21 indexed citations

17.

Johnson, Lisa D. & Stephen C. Jameson. (2010). Self-Specific CD8+ T Cells Maintain a Semi-Naive State Following Lymphopenia-Induced Proliferation. The Journal of Immunology. 184(10). 5604–5611. 17 indexed citations

18.

Tran, Eric, Julie S. Nielsen, Darin A. Wick, et al.. (2010). Polyfunctional T-Cell Responses Are Disrupted by the Ovarian Cancer Ascites Environment and Only Partially Restored by Clinically Relevant Cytokines. PLoS ONE. 5(12). e15625–e15625. 27 indexed citations

19.

Haluszczak, Catherine, Adovi Akue, Sara E. Hamilton, et al.. (2009). The antigen-specific CD8+ T cell repertoire in unimmunized mice includes memory phenotype cells bearing markers of homeostatic expansion. The Journal of Experimental Medicine. 206(2). 435–448. 283 indexed citations

20.

Modiano, Jaime F., Lisa D. Johnson, & Donald Bellgrau. (2008). Negative regulators in homeostasis of naïve peripheral T cells. Immunologic Research. 41(2). 137–153. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact